|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: LEPROT |
Gene summary for LEPROT |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | LEPROT | Gene ID | 54741 |
| Gene name | leptin receptor overlapping transcript | |
| Gene Alias | LEPR | |
| Cytomap | 1p31.3 | |
| Gene Type | protein-coding | GO ID | GO:0006605 | UniProtAcc | A0A087X0N2 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 54741 | LEPROT | P128T-E | Human | Esophagus | ESCC | 1.20e-27 | 1.05e+00 | 0.1241 |
| 54741 | LEPROT | P130T-E | Human | Esophagus | ESCC | 1.31e-60 | 1.65e+00 | 0.1676 |
| 54741 | LEPROT | S42 | Human | Liver | HCC | 3.53e-02 | 5.05e-02 | -0.0103 |
| 54741 | LEPROT | S43 | Human | Liver | Cirrhotic | 8.25e-08 | -1.45e-01 | -0.0187 |
| 54741 | LEPROT | HCC1_Meng | Human | Liver | HCC | 5.11e-84 | -1.09e-01 | 0.0246 |
| 54741 | LEPROT | HCC2_Meng | Human | Liver | HCC | 1.22e-49 | 9.18e-02 | 0.0107 |
| 54741 | LEPROT | cirrhotic1 | Human | Liver | Cirrhotic | 3.15e-19 | 2.92e-01 | 0.0202 |
| 54741 | LEPROT | cirrhotic2 | Human | Liver | Cirrhotic | 1.11e-24 | 2.89e-01 | 0.0201 |
| 54741 | LEPROT | cirrhotic3 | Human | Liver | Cirrhotic | 1.45e-22 | 6.87e-02 | 0.0215 |
| 54741 | LEPROT | p6 | Human | Liver | Cyst | 2.87e-02 | -5.07e-01 | -0.0218 |
| 54741 | LEPROT | HCC1 | Human | Liver | HCC | 3.55e-05 | 2.99e+00 | 0.5336 |
| 54741 | LEPROT | HCC2 | Human | Liver | HCC | 3.18e-05 | 2.95e+00 | 0.5341 |
| 54741 | LEPROT | Pt13.a | Human | Liver | HCC | 1.32e-02 | -9.28e-02 | 0.021 |
| 54741 | LEPROT | Pt13.b | Human | Liver | HCC | 9.26e-24 | 8.07e-02 | 0.0251 |
| 54741 | LEPROT | Pt13.c | Human | Liver | HCC | 2.21e-02 | -3.51e-01 | 0.0076 |
| 54741 | LEPROT | Pt14.b | Human | Liver | HCC | 2.73e-09 | 2.80e-01 | 0.018 |
| 54741 | LEPROT | S014 | Human | Liver | HCC | 1.70e-25 | 1.65e+00 | 0.2254 |
| 54741 | LEPROT | S015 | Human | Liver | HCC | 4.06e-22 | 2.11e+00 | 0.2375 |
| 54741 | LEPROT | S016 | Human | Liver | HCC | 1.03e-30 | 1.86e+00 | 0.2243 |
| 54741 | LEPROT | S027 | Human | Liver | HCC | 1.14e-04 | 9.98e-01 | 0.2446 |
| Page: 1 2 3 4 5 6 7 8 9 10 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00725949 | Cervix | CC | establishment of protein localization to organelle | 99/2311 | 422/18723 | 1.23e-10 | 2.11e-08 | 99 |
| GO:190382910 | Cervix | CC | positive regulation of cellular protein localization | 72/2311 | 276/18723 | 3.20e-10 | 4.46e-08 | 72 |
| GO:005122210 | Cervix | CC | positive regulation of protein transport | 72/2311 | 303/18723 | 2.36e-08 | 1.70e-06 | 72 |
| GO:190495110 | Cervix | CC | positive regulation of establishment of protein localization | 73/2311 | 319/18723 | 9.69e-08 | 5.25e-06 | 73 |
| GO:00068399 | Cervix | CC | mitochondrial transport | 60/2311 | 254/18723 | 4.21e-07 | 1.67e-05 | 60 |
| GO:000660510 | Cervix | CC | protein targeting | 68/2311 | 314/18723 | 2.17e-06 | 6.55e-05 | 68 |
| GO:00903167 | Cervix | CC | positive regulation of intracellular protein transport | 41/2311 | 160/18723 | 3.24e-06 | 8.80e-05 | 41 |
| GO:00323868 | Cervix | CC | regulation of intracellular transport | 71/2311 | 337/18723 | 3.70e-06 | 9.74e-05 | 71 |
| GO:00331579 | Cervix | CC | regulation of intracellular protein transport | 52/2311 | 229/18723 | 8.16e-06 | 1.88e-04 | 52 |
| GO:00705859 | Cervix | CC | protein localization to mitochondrion | 33/2311 | 125/18723 | 1.46e-05 | 2.90e-04 | 33 |
| GO:19016538 | Cervix | CC | cellular response to peptide | 72/2311 | 359/18723 | 1.89e-05 | 3.48e-04 | 72 |
| GO:00323889 | Cervix | CC | positive regulation of intracellular transport | 46/2311 | 202/18723 | 2.45e-05 | 4.24e-04 | 46 |
| GO:00726559 | Cervix | CC | establishment of protein localization to mitochondrion | 31/2311 | 120/18723 | 4.13e-05 | 6.36e-04 | 31 |
| GO:00434349 | Cervix | CC | response to peptide hormone | 77/2311 | 414/18723 | 1.40e-04 | 1.70e-03 | 77 |
| GO:00161977 | Cervix | CC | endosomal transport | 48/2311 | 230/18723 | 1.65e-04 | 1.97e-03 | 48 |
| GO:00713757 | Cervix | CC | cellular response to peptide hormone stimulus | 57/2311 | 290/18723 | 2.32e-04 | 2.59e-03 | 57 |
| GO:00066269 | Cervix | CC | protein targeting to mitochondrion | 25/2311 | 100/18723 | 3.80e-04 | 3.89e-03 | 25 |
| GO:00070347 | Cervix | CC | vacuolar transport | 34/2311 | 157/18723 | 7.03e-04 | 6.40e-03 | 34 |
| GO:19037475 | Cervix | CC | regulation of establishment of protein localization to mitochondrion | 15/2311 | 50/18723 | 7.36e-04 | 6.60e-03 | 15 |
| GO:19032144 | Cervix | CC | regulation of protein targeting to mitochondrion | 13/2311 | 44/18723 | 1.90e-03 | 1.40e-02 | 13 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| LEPROT | deletion | Frame_Shift_Del | novel | c.165delC | p.Ile56SerfsTer47 | p.I56Sfs*47 | protein_coding | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | |||
| LEPROT | deletion | Frame_Shift_Del | novel | c.87delT | p.Met31CysfsTer6 | p.M31Cfs*6 | protein_coding | TCGA-EW-A2FV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | docetaxel | SD | |||
| LEPROT | SNV | Missense_Mutation | novel | c.373N>G | p.Phe125Val | p.F125V | protein_coding | deleterious(0) | probably_damaging(0.955) | TCGA-G4-6586-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| LEPROT | insertion | Frame_Shift_Ins | novel | c.70dupG | p.Ala24GlyfsTer44 | p.A24Gfs*44 | protein_coding | TCGA-AA-A02R-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |||
| LEPROT | SNV | Missense_Mutation | c.254N>A | p.Gly85Glu | p.G85E | protein_coding | deleterious(0) | probably_damaging(0.984) | TCGA-BS-A0UV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | ||
| LEPROT | SNV | Missense_Mutation | novel | c.346N>A | p.Ala116Thr | p.A116T | protein_coding | tolerated(0.56) | benign(0.031) | TCGA-D1-A16X-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| LEPROT | SNV | Missense_Mutation | novel | c.373N>C | p.Phe125Leu | p.F125L | protein_coding | deleterious(0.02) | probably_damaging(0.928) | TCGA-EO-A3AY-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | PD | |
| LEPROT | SNV | Missense_Mutation | novel | c.358N>A | p.Leu120Ile | p.L120I | protein_coding | tolerated(0.37) | benign(0.073) | TCGA-53-7626-01 | Lung | lung adenocarcinoma | Female | >=65 | I/II | Unspecific | Cisplatin | PD | |
| LEPROT | SNV | Missense_Mutation | novel | c.151N>T | p.His51Tyr | p.H51Y | protein_coding | tolerated(1) | benign(0) | TCGA-86-7954-01 | Lung | lung adenocarcinoma | Female | >=65 | I/II | Chemotherapy | carboplatin | CR | |
| LEPROT | SNV | Missense_Mutation | novel | c.121G>T | p.Val41Phe | p.V41F | protein_coding | deleterious(0.05) | possibly_damaging(0.881) | TCGA-97-7941-01 | Lung | lung adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |